People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2012 |
| Decibel Therapeutics, Inc. | — | Biotechnology | Series C | $87.1M | $2.0B | 2015 |
| MyoKardia Inc | — | Biotechnology | Series C | $60.0M | $1.9B | 2012 |
| Afferent Pharmaceuticals, Inc. | — | Other Health Care | Series C | $58.1M | $1.3B | 2009 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2010 |
Kevin Starr at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Starr on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mitchell S. Bloom | 2 | 7 |
| Peter Barrett | 1 | 18 |
| Bruce Booth | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| David Guyer | 1 | 8 |
| Jens Eckstein | 1 | 8 |
| David Neafus | 1 | 7 |
| Michael Solomon | 1 | 7 |
| Mark Perry | 1 | 6 |
| ABBIE CELNIKER | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Peter A. Thompson | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| THOMAS HUGHES | 1 | 4 |
| Charles Homcy | 1 | 4 |
| Neil A. Exter | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.